Skip to Content

Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia

HAMBURG, Germany and OXFORD, England, August 28, 2007 /PRNewswire-FirstCall/ -- Evotec AG is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at 11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST

The Evotec speakers at the worldsleep07 congress and in the webcast and conference call will be:

- Dr John Kemp, Chief Research and Development Officer

- Dr Tim Tasker, Executive Vice President Clinical Development

Evotec will host a poster presentation on the study results at the worldsleep07 congress from 4.00 to 6.00 pm AEST time at the Sofitel Reef Hotel, 35-41 Wharf Street, Cairns, Australia (poster No PO649). Following the conference presentation, Evotec will hold the webcast and conference call to discuss the results. Positive headline results of this first Phase II study in 67 patients were released on 4 June 2007.

To attend the webcast and conference call, please dial in using the following phone numbers:

    Australia    +61-(2)-8223-9234

    Germany      +49-(69)-9897-2631

    Switzerland  +41-(44)-800-9659

    UK           +44-(20)-7138-0814

    USA          +1-(718)-354-1157

    PIN code: 5301349

Please dial in 10 minutes before the beginning of the conference.

The presentation will be available at the Evotec homepage

Evotec expects the results from a second Phase II study in 135 elderly insomniacs to be available in October 2007.

Although certain aspects of insomnia are addressed by current treatments, there is no drug yet available which meets all the needs of insomnia patients.

About EVT 201

EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. Acting on GABAA receptors it addresses the gold standard mechanism for insomnia with more than 90% of current insomnia drugs using this mechanism. Importantly, however, its close to ideal half life of 3 to 4 hours and its partial agonist activity gives EVT 201 a differentiated preclinical profile and mechanism of action.

The headline results of the first Phase II study with EVT 201 were very positive in terms of all aspects of the problems faced by insomniacs, i.e. sleep onset and sleep maintenance and yet the patients didn't feel any drug hang-over effects after waking in the morning. Furthermore, in two previous Phase I/II proof-of-principle studies in subjects with induced insomnia, EVT 201 significantly reduced Wake After Sleep Onset (WASO) while significantly increasing the Total Sleep Time (TST) and quality of sleep with no subjective residual effects. The studies were conducted in a sleep laboratory setting using the traffic noise model of insomnia in healthy male volunteers. In this setting an average of 52 decibels of recorded traffic noise is played throughout the night thereby provoking insomnia. This model has been used to evaluate several insomnia treatments currently in development and on the market. EVT 201 showed no tolerance/dependence liabilities in pre-clinical studies and no interaction with alcohol.

    Joern Aldag

    President & Chief Executive Office

    T: +49-(0)40-560-81-242

    F: +49-(0)40-560-81-333


    Anne Hennecke

    Senior Vice President

    Investor Relations & Corporate Communications

    T: +49-(0)40-560-81-286

    F: +49-(0)40-560-81-333


    Evotec AG (Headquarters)

    Schnackenburgallee 114

    22525 Hamburg, Germany

CONTACT: Joern Aldag, President & Chief Executive Office, T:+49-(0)40-560-81-242, F: +49-(0)40-560-81-333, ; AnneHennecke, Senior Vice President, Investor Relations & CorporateCommunications, T: +49-(0)40-560-81-286, F: +49-(0)40-560-81-333,; Evotec AG (Headquarters), Schnackenburgallee 114,22525 Hamburg, Germany

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: August 2007